Fibrotech Therapeutics

About

Fibrotech Therapeutics develops proprietary small-molecule tranilast analogues as orally bioavailable antifibrotic drugs, advancing lead candidate FT011 for diabetic nephropathy and broader fibrotic/inflammatory indications.

Mission

Fibrotech Therapeutics is developing proprietary small-molecule analogues of tranilast as antifibrotic therapies, with lead candidate FT011 targeted at diabetic nephropathy. FT011 is orally bioavailable and has significantly inhibited progression of renal fibrosis in a rat model of diabetic nephropathy. The company plans to advance FT011 through clinical development, aiming to complete Phase Ib trials and test first patients within 18–24 months, with Phase I trials targeted for 2010. Fibrotech intends to seek partnering or sale of the FT011 program following Phase II and to expand indications to inflammatory conditions, pulmonary fibrosis, liver cirrhosis and chronic heart disease. Financially, the company has secured investment to fund near-term clinical development and has also received a Type 1 Diabetes RAID Grant from the US NIH. Fibrotech was formed by Assoc Prof Darren Kelly of the University of Melbourne and St Vincent’s Hospital with support from Melbourne Ventures.

Quick Facts